Poxel Announces its Financial Calendar for 2018

Lyon, France, December 19, 2017 – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announces its schedule for the publication of financial information for 2018.

*Subject to modification

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

Contacts

Poxel SA

Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relation
jonae.barnes@poxelpharma.com
+1 617 818 2985

Released December 19, 2017